EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ivermectin repurposing for COVID-19: pharmacological and bibliometric analysis

Maresa Dulle, Roland Seifert

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04233-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Maresa Dulle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. Hauptthemen laut MEDLINE: Ivermectin, COVID-19 Drug Treatment, Drug Repositioning, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the onset of the COVID-19 pandemic in March 2020, researchers worldwide have sought effective drugs to prevent and manage SARS-CoV-2 and its spectrum of symptoms. Ivermectin, originally developed as an anthelmintic for controlling parasitic infections in humans and animals, has drawn attention based on the hypothesis that it inhibits viral replication. In Austria, ivermectin usage peaked in November 2021, following promotion by the right-wing Freedom Party of Austria (FPÖ) as an alternative treatment to vaccination, resonating strongly within anti-vaccine and skeptical communities. The topic is also very present in the United States of America due to the re-election of D. Trump as US President and the designation of R. Kennedy as the United States’ Secretary of Health and Human Services. To critically examine the controversial use of ivermectin for COVID-19 and publication trends during the pandemic, this study analysed all publications listed in PubMed from 1 January 2020 to 31 December 2022 using the keywords ‘ivermectin’ and ‘COVID-19’, resulting in a dataset of 353 publications. These publications were assessed for scientific quality, methodological rigour and bias, with particular focus on the influence of social and political dynamics on publication practices, as well as the prevalence of preprints, citation trends and the role of funding sources. Our study shows that many highly cited studies on ivermectin display methodological weaknesses and data gaps, contributing to the propagation of hypotheses lacking substantial empirical support. This analysis underscores the necessity of rigorous quality control during crises and highlights the long-term risks posed to scientific databases and public health by methodologically deficient research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvermectinCOVID-19 Drug TreatmentDrug RepositioningAntiviral AgentsHumansBibliometricsCOVID-19SARS-CoV-2Animals

Stichwörter der Autor:innen

Antiviral treatmentCOVID-19Citation analysisDrug repurposingEvidence-based medicineIvermectinMethodological biasPandemicPreprintsSARS-CoV-2

Substanzen

IvermectinAntiviral Agents

Autor:innen und Institutionen

  • Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.
  • Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. seifert.roland@mh-hannover.de.

Förderung

  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Dulle, M., & Seifert, R. (2025). Ivermectin repurposing for COVID-19: pharmacological and bibliometric analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04233-5

Vancouver

Dulle M, Seifert R. Ivermectin repurposing for COVID-19: pharmacological and bibliometric analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04233-5

BibTeX
@article{Dulle2025,
  author = {Dulle, Maresa and Seifert, Roland},
  title = {Ivermectin repurposing for COVID-19: pharmacological and bibliometric analysis},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04233-5}
}
Kostenlos starten →